The Novavax COVID-19 vaccine has been found to have more than 90 per cent efficacy, paving the way for it to be available later this year in Australia.
The successful results from the phase 3 clinical trial of more than 30,000 volunteers in the United States and Mexico puts Novavax on track to have its two-dose vaccine approved in the US and elsewhere in the third quarter of 2021.
It backs up results of a UK study, released in January, that showed a similar efficacy in preventing infection from coronavirus.
What is Novavax?
Novavax is an American company based in the state of Maryland.
It was founded in 1987 and focuses on producing vaccines for COVID-19, as well as other serious diseases, such as Ebola and the flu.
The company's COVID-19 vaccine is officially called NVX-CoV2373.
Anti-Vaxers have Rocks Between their Ears
No comments:
Post a Comment